Anti-Von Willebrand Factor antibody [F8/86] (ab778)

Overview

  • Product nameAnti-Von Willebrand Factor antibody [F8/86]
    See all Von Willebrand Factor primary antibodies
  • Description
    Mouse monoclonal [F8/86] to Von Willebrand Factor
  • Tested applicationsSuitable for: IHC-P, IHC-Frmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Rabbit
  • Immunogen

    Von Willebrand Factor isolated from human plasma.

Properties

Applications

Our Abpromise guarantee covers the use of ab778 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/15 - 1/30. Perform enzymatic antigen retrieval before commencing with IHC staining protocol.
IHC-Fr 1/15 - 1/30. ABC method. We suggest an incubation period of 60 minutes at room temperature.

Target

  • FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
  • Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 4 TIL (trypsin inhibitory-like) domains.
    Contains 3 VWFA domains.
    Contains 3 VWFC domains.
    Contains 4 VWFD domains.
  • DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
  • Post-translational
    modifications
    All cysteine residues are involved in intrachain or interchain disulfide bonds.
    N- and O-glycosylated.
  • Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
  • Information by UniProt
  • Database links
  • Alternative names
    • Coagulation factor VIII antibody
    • Coagulation factor VIII VWF antibody
    • F8VWF antibody
    • Factor VIII related antigen antibody
    • von Willebrand antigen 2 antibody
    • von Willebrand antigen II antibody
    • Von Willebrand disease antibody
    • VWD antibody
    • vWF antibody
    • VWF_HUMAN antibody
    see all

Anti-Von Willebrand Factor antibody [F8/86] images

  • Formalin fixed paraffin embedded human tonsil stained with Von Willebrand Factor using ABC and AEC chromogen.

References for Anti-Von Willebrand Factor antibody [F8/86] (ab778)

This product has been referenced in:
  • Wang Y  et al. The transplantation of Akt-overexpressing amniotic fluid-derived mesenchymal stem cells protects the heart against ischemia-reperfusion injury in rabbits. Mol Med Rep 14:234-42 (2016). IHC-P ; Rabbit . Read more (PubMed: 27151366) »
  • Lee DY  et al. Synergistic effect of laminin and mesenchymal stem cells on tracheal mucosal regeneration. Biomaterials 44:134-42 (2015). IHC-P ; Rabbit . Read more (PubMed: 25617133) »

See all 6 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: citrate buffer
Sample Rabbit Tissue sections (trachea)
Specification trachea
Permeabilization Yes - triton X-100
Fixative Paraformaldehyde
Username

Ms. Hee-Bok Kim

Verified customer

Submitted Jun 05 2014

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step 1% BSA + 5% NGS + 0.1% Sapo as blocking agent for 30 minute(s) · Concentration: 100% · Temperature: 20°C
Antigen retrieval step None
Sample Human Tissue sections (blood vessels)
Specification blood vessels
Permeabilization Yes - saponine
Fixative Formaldehyde
Username

Abcam user community

Verified customer

Submitted Mar 24 2014

Thank you for contacting us.

The lab sent me the following information regarding your question:

Based on the data Factor VIII reacts specifically with the endothelial cells of normal, reactive, and neoplastic blood and lymphatic ve...

Read More

Thank you for contacting us.

I have emailed the lab to check regarding the specificity testing, and I'll let you know what I find out.
The IHC image on the datasheet is from the lab.

The immunogen used to raise the antibody wa...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"